Magenta Therapeutics will continue to advance its investigational conditioning therapy CD45-ADC for patients with autoimmune diseases undergoing stem cell transplants, the company highlighted in a progress report.
CD45-ADC is a therapy designed to remove disease-causing immune cells in a safer way when preparing patients for a stem cell transplant to treat autoimmune conditions such as multiple sclerosis (MS). Given the promising early results in mouse models of MS, Magenta plans to continue its preclinical tests to collect enough data to request the permission of the U.S. Food and Drug Administration (FDA) to start the first clinical tests in humans.
The plan is part of the company’s 2020 goals, which were presented at the 38th Annual J.P. Morgan Healthcare Conference, held this week in California.
While standard-of-care for MS involves years of continued medical treatment, a stem cell transplant — to reset the patient’s immune system and replace it with a healthy one — has demonstrated durable remission in thousands of patients with autoimmune diseases, Magenta said.
Yet, only a fraction of patients are eligible for a transplant, in part due to the toxicity associated with current treatments that outweighs the potential benefits.
A stem cell transplant involves two main steps: removing the self-reactive, disease-causing cells (a process also known as conditioning), and replacing them with healthy blood-forming (hematopoietic) stem cells to regenerate a healthy immune system.
Patients with autoimmune diseases undergo an autologous transplant, which means the patient’s own stem cells are used in the procedure.
Current conditioning regimens to deplete the ill immune system consist of toxic, and non-specific chemotherapy or radiation. These treatments can lead to significant side effects including infertility, cancer, organ damage, or death.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?